<SEC-DOCUMENT>0001213900-26-054785.txt : 20260512
<SEC-HEADER>0001213900-26-054785.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512092747
ACCESSION NUMBER:		0001213900-26-054785
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260512
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearmind Medicine Inc.
		CENTRAL INDEX KEY:			0001892500
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41557
		FILM NUMBER:		26966185

	BUSINESS ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
		BUSINESS PHONE:		972-54-5704749

	MAIL ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0290311-6k_clearmind.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: May 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-41557</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>CLEARMIND
MEDICINE INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>101 &ndash; 1220 West 6th Avenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Vancouver, British Columbia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Form 40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Attached hereto and incorporated herein is the Registrant&rsquo;s
press release issued on May 12, 2026, titled &ldquo;Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated
in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The first three paragraphs of the press release
attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant&rsquo;s Registration Statements on&nbsp;Form
F-3 (File Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1892500/000121390023094809/ea189816-f3_clearmind.htm">333-275991</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1892500/000121390024004506/ea191622-posam_clearmind.htm">333-270859</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1892500/000121390024004506/ea191622-posam_clearmind.htm">333-273293</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1892500/000121390026017379/ea0277219-f3_clear.htm">333-293521</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1892500/000121390026050265/ea0288494-f3_clearmind.htm">333-295455</A>) and Form S-8 (File No.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1892500/000121390024107014/ea0224059-s8_clearmind.htm">333-283695</A>),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="ea029031102ex99-1.htm">Press release titled: &ldquo;Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Clearmind Medicine, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: May 12, 2026</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Adi Zuloff-Shani</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Adi Zuloff-Shani</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029031102ex99-1.htm
<DESCRIPTION>PRESS RELEASE TITLED: "CLEARMIND MEDICINE REACHES IMPORTANT CLINICAL MILESTONE: 20 PARTICIPANTS NOW TREATED IN ONGOING PHASE I/IIA TRIAL OF CMND-100 FOR ALCOHOL USE DISORDER"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="ea029031102_ex99-1img1.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants
Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine
Inc. (Nasdaq: CMND) (&ldquo;Clearmind&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biotech company focused on the discovery and
development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems,
today announced that two additional participants have been successfully dosed in the fourth cohort of its FDA-approved Phase I/IIa clinical
trial evaluating CMND-100 (MEAI) for the treatment of moderate to severe Alcohol Use Disorder (AUD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This milestone brings the total number of participants treated to date
across all cohorts to 20, reflecting strong momentum and continued progress in the multinational, multicenter study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The two newly dosed patients in the fourth cohort were treated at Hadassah-University
Medical Center in Jerusalem, Israel, one of the key active trial sites. The fourth cohort features a higher dose of CMND-100 (160 mg),
following the positive Data and Safety Monitoring Board (DSMB) recommendation and successful completion of the third cohort in April 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Building on highly encouraging safety and tolerability data from the
first three cohorts (which included 18 participants and met the primary safety endpoint with no serious adverse events reported), the
Company continues to advance the dose-escalation phase of the trial. Previous cohorts demonstrated a favorable safety profile consistent
with earlier results, supporting further evaluation of CMND-100&rsquo;s potential as a novel, non-hallucinogenic treatment option for
AUD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Reaching the 20- participants milestone and successfully initiating
dosing in the fourth cohort at our Israeli site is an important step forward,&rdquo; said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive
Officer of Clearmind Medicine. &ldquo;The consistent safety data observed so far across all cohorts reinforces our confidence in CMND-100
and brings us closer to potentially delivering a much-needed new therapeutic option for patients struggling with alcohol use disorder.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ongoing FDA-approved Phase I/IIa trial is a multinational, multicenter
study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate
to severe AUD. The trial is being conducted at leading institutions including Yale School of Medicine, Johns Hopkins University School
of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Clearmind Medicine Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech
company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve
widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s intellectual portfolio currently consists of nineteen
patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and
will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares of Clearmind are listed for trading on Nasdaq under the symbol
&ldquo;CMND.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, visit:&nbsp;https://www.clearmindmedicine.com&nbsp;or
contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations<BR>
invest@clearmindmedicine.com<BR>
www.Clearmindmedicine.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates&rdquo; and similar expressions
or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements
when it discusses the timing and progress of it clinical trials and potentially delivering a much-needed new therapeutic option for patients
struggling with alcohol use disorder.&nbsp;Forward-looking statements are not historical facts, and are based upon management&rsquo;s
current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith.&nbsp;However, there can be no assurance that management&rsquo;s expectations, beliefs and projections
will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is&nbsp;made
to the Company&rsquo;s reports filed from time to time with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), including, but
not limited to, the risks detailed in the Company&rsquo;s annual report on Form 20-F for the fiscal year ended October 31,&nbsp;2025&nbsp;and
subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates
with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience,
and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible
for the contents of third-party websites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029031102_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029031102_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N 2P# 2(  A$! Q$!_\0
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M3G+^P/;UQ6UXM^&NK>$;!+Z:XM[NU+A'>$$&,GID'L>F:VO@A_R.MW_UX/\
M^AI7I/Q:_P"2;:E_O1?^C%JG)\U@L>&:!8:]XP>S\-6=PSVL!:9$E8^5 #C+
M'^@]^.IJ]XN^'6J>$+.*]N9[>[M)'$9DA!&QB. 0>QQUKHO@9_R-6I_]>/\
M[.M=[\8O^2<W?_7>'_T,4.34K 8GP2URYO=(O])N93(MBR- 6.2J-GY?H"./
MK7GOQ8_Y*/J_TB_]%+76_ ?_ (_]<_ZY0_S:N2^*_P#R4?5_I%_Z*6DOB#H>
MRZC_ ,D8D_[ 8_\ 1(KYXT2RU'4]4CTW2MWVF\!APK;05/+;C_=P,GZ5]#ZC
M_P D8D_[ 8_]$BO(O@__ ,E'L_\ KA-_Z#1'9@Q?$GPIUKPUHLFIM=6MW!"
M9EA#!D'KSU K7^"FNW%OX@N-":1FM+F%ID0GA)%QDCZ@G/T%>L>.O^1$UO\
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GRD#+R92>GL*^IA'$B+"L:!,8"A1@?A2[8?\ GFO_ 'R*?/Y!8__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
